PRR11 and metastatic malignant neoplasm in the lymph nodes: In 109 BRCA patients and 260 ER+ BRCA patients, PRR11 promotes more lymph node metastasis, higher Ki-67 ratio and endocrine resistance, thus diminishing the overall survival, recurrence-free survival and relapse-free survival [1,5,40].